149 related articles for article (PubMed ID: 31342356)
1. Survival Outcomes for Patients With Clinical Complete Response After Neoadjuvant Chemotherapy: Is Omitting Surgery an Option?
Özkurt E; Sakai T; Wong SM; Tukenmez M; Golshan M
Ann Surg Oncol; 2019 Oct; 26(10):3260-3268. PubMed ID: 31342356
[TBL] [Abstract][Full Text] [Related]
2. Oncologic safety of breast-conserving surgery compared to mastectomy in patients receiving neoadjuvant chemotherapy for locally advanced breast cancer.
Cho JH; Park JM; Park HS; Park S; Kim SI; Park BW
J Surg Oncol; 2013 Dec; 108(8):531-6. PubMed ID: 24115142
[TBL] [Abstract][Full Text] [Related]
3. Impact of multifocal or multicentric disease on surgery and locoregional, distant and overall survival of 6,134 breast cancer patients treated with neoadjuvant chemotherapy.
Ataseven B; Lederer B; Blohmer JU; Denkert C; Gerber B; Heil J; Kühn T; Kümmel S; Rezai M; Loibl S; von Minckwitz G
Ann Surg Oncol; 2015 Apr; 22(4):1118-27. PubMed ID: 25297900
[TBL] [Abstract][Full Text] [Related]
4. The Association of Extent of Axillary Surgery and Survival in Women with N2-3 Invasive Breast Cancer.
Park TS; Thomas SM; Rosenberger LH; Fayanju OM; Plichta JK; Blitzblau RC; Ong CT; Hyslop T; Hwang ES; Greenup RA
Ann Surg Oncol; 2018 Oct; 25(10):3019-3029. PubMed ID: 29978365
[TBL] [Abstract][Full Text] [Related]
5. Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017.
McGuire KP; Hwang ES; Cantor A; Golshan M; Meric-Bernstam F; Horton JK; Nanda R; Amos KD; Forero A; Hudis CA; Meszoely I; De Los Santos JF
Ann Surg Oncol; 2015 Jan; 22(1):75-81. PubMed ID: 25059792
[TBL] [Abstract][Full Text] [Related]
6. Impact of Time from Completion of Neoadjuvant Chemotherapy to Surgery on Survival Outcomes in Breast Cancer Patients.
Sanford RA; Lei X; Barcenas CH; Mittendorf EA; Caudle AS; Valero V; Tripathy D; Giordano SH; Chavez-MacGregor M
Ann Surg Oncol; 2016 May; 23(5):1515-21. PubMed ID: 26678405
[TBL] [Abstract][Full Text] [Related]
7. Leveraging the increased rates of pathologic complete response after neoadjuvant treatment in breast cancer to de-escalate surgical treatments.
Esgueva A; Siso C; Espinosa-Bravo M; Sobrido C; Miranda I; Salazar JP; Rubio IT
J Surg Oncol; 2021 Jan; 123(1):71-79. PubMed ID: 33002230
[TBL] [Abstract][Full Text] [Related]
8. Oncologic Safety of Immediate Breast Reconstruction in Breast Cancer Patients Who Underwent Neoadjuvant Chemotherapy: Short-Term Outcomes of a Matched Case-Control Study.
Ryu JM; Park S; Paik HJ; Nam SJ; Kim SW; Lee SK; Yu J; Bae SY; Kim I; Bang SI; Mun GH; Pyon JK; Jeon BJ; Lee JE
Clin Breast Cancer; 2017 Jun; 17(3):204-210. PubMed ID: 28065399
[TBL] [Abstract][Full Text] [Related]
9. Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials.
Krug D; Lederer B; Seither F; Nekljudova V; Ataseven B; Blohmer JU; Costa SD; Denkert C; Ditsch N; Gerber B; Hanusch C; Heil J; Hilfrich J; Huober JB; Jackisch C; Kümmel S; Paepke S; Schem C; Schneeweiss A; Untch M; Debus J; von Minckwitz G; Kühn T; Loibl S
Ann Surg Oncol; 2019 Nov; 26(12):3892-3901. PubMed ID: 31350646
[TBL] [Abstract][Full Text] [Related]
10. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.
Pesce C; Liederbach E; Wang C; Lapin B; Winchester DJ; Yao K
Ann Surg Oncol; 2014 Oct; 21(10):3231-9. PubMed ID: 25081341
[TBL] [Abstract][Full Text] [Related]
11. Impact of Residual Nodal Disease Burden on Technical Outcomes of Sentinel Lymph Node Biopsy for Node-Positive (cN1) Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Laws A; Hughes ME; Hu J; Barry WT; Dominici L; Nakhlis F; Barbie T; Duggan M; Weiss A; Rhei E; Carter K; Nimbkar S; Schnitt SJ; King TA
Ann Surg Oncol; 2019 Nov; 26(12):3846-3855. PubMed ID: 31222687
[TBL] [Abstract][Full Text] [Related]
12. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma.
Thornton MJ; Williamson HV; Westbrook KE; Greenup RA; Plichta JK; Rosenberger LH; Gupta AM; Hyslop T; Hwang ES; Fayanju OM
Ann Surg Oncol; 2019 Oct; 26(10):3166-3177. PubMed ID: 31342392
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy increases the rate of breast conservation in lobular-type breast cancer patients.
Fitzal F; Mittlboeck M; Steger G; Bartsch R; Rudas M; Dubsky P; Riedl O; Jakesz R; Gnant M
Ann Surg Oncol; 2012 Feb; 19(2):519-26. PubMed ID: 21743980
[TBL] [Abstract][Full Text] [Related]
15. Clinical benefit from neoadjuvant chemotherapy in oestrogen receptor-positive invasive ductal and lobular carcinomas.
Delpech Y; Coutant C; Hsu L; Barranger E; Iwamoto T; Barcenas CH; Hortobagyi GN; Rouzier R; Esteva FJ; Pusztai L
Br J Cancer; 2013 Feb; 108(2):285-91. PubMed ID: 23299541
[TBL] [Abstract][Full Text] [Related]
16. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
De La Cruz LM; Harhay MO; Zhang P; Ugras S
Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of axillary nodal imaging by magnetic resonance imaging based on breast cancer subtype after neoadjuvant chemotherapy.
Steiman J; Soran A; McAuliffe P; Diego E; Bonaventura M; Johnson R; Ahrendt G; McGuire K
J Surg Res; 2016 Jul; 204(1):237-41. PubMed ID: 27451892
[TBL] [Abstract][Full Text] [Related]
18. Long-term survival outcomes following internal mammary node irradiation in stage II-III breast cancer: results of a large retrospective study with 12-year follow-up.
Chang JS; Park W; Kim YB; Lee IJ; Keum KC; Lee CG; Choi DH; Suh CO; Huh SJ
Int J Radiat Oncol Biol Phys; 2013 Aug; 86(5):867-72. PubMed ID: 23747215
[TBL] [Abstract][Full Text] [Related]
19. Tumor response ratio predicts overall survival in breast cancer patients treated with neoadjuvant chemotherapy.
Miller M; Ottesen RA; Niland JC; Kruper L; Chen SL; Vito C
Ann Surg Oncol; 2014 Oct; 21(10):3317-23. PubMed ID: 25059788
[TBL] [Abstract][Full Text] [Related]
20. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
